TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06186219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is a monoclonal antibody that targets cluster of differentiate 20 (CD20) present on B-cells and lowers humoral immunity. Rituximab has been used successfully as a desensitization agent to treat Highly Human Leukocyte Antigens (HLA)-sensitized patients planning renal transplant. All cases of antibody-mediated rejection were seen in the placebo group, none in the Rituximab group. Rituximab has been safely used with Methotrexate in the treatment of Rheumatoid Arthritis, where co-administration of Methotrexate and Rituximab results in better outcomes than either medication alone.~We propose this safety and feasibility open-label trial that will examine if Rituximab pre-treatment before Standard-of-Care Methotrexate-Pegloticase will result in recapture of Pegloticase efficacy as measured by serum urate (SU) \< 6 mg/dL throughout the trial and up to 6-months of Methotrexate-Pegloticase administration.
Study: NCT05659238

Intervention type: BEHAVIORAL
Intervention: the effect on language development & attention
Description: Tv \& other electronic devices effects onn children's language development \& attention

Intervention type: BEHAVIORAL
Intervention: the effect on language development & attention
Description: Tv \& other electronic devices effects onn children's language development \& attention
Study: NCT05132439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: Oral medication typically used for Type 2 diabetes with presumed anti-inflammatory properties

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matched to active study drug
Study: NCT06471179

Intervention type: DEVICE
Intervention: Functional MRI
Description: Functional Magnetic Resonance Imaging during rest for minutes and analysis of data obtained from resting fMRI

Intervention type: DEVICE
Intervention: Functional MRI
Description: Functional Magnetic Resonance Imaging during rest for minutes and analysis of data obtained from resting fMRI
Study: NCT03975946

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood Sample
Description: Biological analysis

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Shamapheresis procedure
Description: Shamapheresis is performed with the same automated monitor (Plasauto, HemaT company). Extracted plasma is not treated through the secondary filter (Rheofilter) and return to the patient. This technique is performed in tandem with a hemodialysis monitor.
Study: NCT05737680

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 400mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine continued
Study: NCT04620980

Intervention type: DIAGNOSTIC_TEST
Intervention: targeted resequencing
Description: The investigators will use a disease-specific gene panel including about 100 genes related to Parkinson's Disease, autophagy and levodopa induced Dyskinesia (LID).

Intervention type: DIAGNOSTIC_TEST
Intervention: targeted resequencing
Description: The investigators will use a disease-specific gene panel including about 100 genes related to Parkinson's Disease, autophagy and levodopa induced Dyskinesia (LID).
Study: NCT06187701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Co-Active Therapeutic Theatre (Co-ATT)
Description: There will be one group drama therapy session per week, for a total of twelve weeks (i.e., total twelve sessions) followed by a single performance (with composition of the audience determined by unanimous agreement of the participants) of the dramatic work (script) produced by the participants during the course of the drama therapy intervention.
Study: NCT05343455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD-29
Description: DFD-29 (40 mg) extended release capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Doxycycline 40 mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT06570759

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early intervention for OMI
Description: Early PCI for OMI (+) STEMI (-) patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard early intervention for STEMI
Description: Early PCI for OMI (+) and STEMI (+) patients

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard early intervention for STEMI
Description: Early PCI for OMI (+) and STEMI (+) patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard delayed intervention for NSTEMI
Description: Medical stabilization and then PCI for OMI (-) and STEMI (-) patients

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard delayed intervention for NSTEMI
Description: Medical stabilization and then PCI for OMI (-) and STEMI (-) patients
Study: NCT06540287

Intervention type: OTHER
Intervention: Observational
Description: No intervention

Intervention type: OTHER
Intervention: Observational
Description: No intervention
Study: NCT06144684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GUB014295
Description: GUB014295 is a long-acting amylin analogue in development, a single subcutaneous dose is administered in part 1, multiple doses administered in part 2 of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GUB014295-PLACEBO
Description: GUB014295-PLACEBO is matching GUB014295 in appearance, a single subcutaneous dose is administered in part 1, multiple doses administered in part 2 of the study
Study: NCT06051162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BP management with HPI guidance
Description: The hemodynamic condition of the HPI group will be managed by HPI guidance which is derived by arterial pressure waveform information, including Eadyn, SVV, dP/dt.
Study: NCT06497985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucidinostat
Description: 30mg orally BIW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200 mg intravenously (IV) Q3W
Study: NCT05290207

Intervention type: DIAGNOSTIC_TEST
Intervention: The hyperinsulinaemic hypoglycaemic clamp
Description: Glucose will be clamped at 5.0 mmol/L for approximately 30 minutes, and then be lowered to 3.0 mmol/L for 30 minutes

Intervention type: DIAGNOSTIC_TEST
Intervention: The hyperinsulinaemic hypoglycaemic clamp
Description: Glucose will be clamped at 5.0 mmol/L for approximately 30 minutes, and then be lowered to 3.0 mmol/L for 30 minutes

Intervention type: DIAGNOSTIC_TEST
Intervention: The hyperinsulinaemic hypoglycaemic clamp
Description: Glucose will be clamped at 5.0 mmol/L for approximately 30 minutes, and then be lowered to 3.0 mmol/L for 30 minutes

Intervention type: DIAGNOSTIC_TEST
Intervention: The hyperinsulinaemic hypoglycaemic clamp
Description: Glucose will be clamped at 5.0 mmol/L for approximately 30 minutes, and then be lowered to 3.0 mmol/L for 30 minutes
Study: NCT06022822

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study: NCT05661214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teaching
Description: The intervention in this study is teaching. Researchers, will create a pressure injury teaching content and assess this effectiveness and also, intervention groups will use Clinical Decision Support System (CDSS) as a tool to plan nursing interventions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teaching
Description: The intervention in this study is teaching. Researchers, will create a pressure injury teaching content and assess this effectiveness and also, intervention groups will use Clinical Decision Support System (CDSS) as a tool to plan nursing interventions.
Study: NCT05560035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg for the next 22h.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline (NS)
Description: Patients are received equal volumes of saline intravenously until the end of the surgery
Study: NCT06328569

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Therapy
Description: The therapist begins by assessing the patient's swallowing abilities and creating a personalized treatment plan. This involves determining the appropriate Virtual Reality Therapy scenarios, difficulty levels, and specific swallowing goals tailored to the patient's condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional dysphagia treatment
Description: Conventional dysphagia treatment included oropharyngeal muscle movement training, orofacial alternating hot and cold stimulation, Masako swallowing training, Mendelsohn maneuver, therapeutic ingestion training, intermittent oral-esophageal tube feeding, etc., 30 min each time, once a day for 14 consecutive days.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional dysphagia treatment
Description: Conventional dysphagia treatment included oropharyngeal muscle movement training, orofacial alternating hot and cold stimulation, Masako swallowing training, Mendelsohn maneuver, therapeutic ingestion training, intermittent oral-esophageal tube feeding, etc., 30 min each time, once a day for 14 consecutive days.
Study: NCT06230146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin group
Description: Fractional ablative laser followed by Intralesional insulin injection (Human actrapid insulin 100 IU\\ml solution).~Dose: injection of 0.1 ml\\cm3 of the lesion avoiding subcutaneous injection as much as possible especially in fatty areas.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin group
Description: Fractional ablative laser followed by intralesional Botox-A (100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2 mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 5 U/0.1 mL),It will be injected into the body of the keloid with the help of a 24gauge needle at a distance of 1 cm apart until slight blanching is visible. The dose will be adjusted to 2.5 U/cm3 of the lesion, not exceeding 100 units per session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide group
Description: Fractional ablative laser followed by Triamcinolone acetonide injection. TAC 40 mg/ml will be diluted with normal saline solution 0.9% to the concentration of 20 mg/ml .Maximum drug injected during each session will be 40 mg triamcinolone.
Study: NCT05398666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: White LED light
Description: Participants will be exposed to white LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: White LED light
Description: Participants will be exposed to white LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Green LED light
Description: Participants will be exposed to green LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Green LED light
Description: Participants will be exposed to green LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.
Study: NCT06642701

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Impedance Tomography
Description: According to the results of traditional assessment, physiotherapists and clinicians discussed the EIT results to give respiratory rehabilitation chest physiotherapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: chest physiotherapy
Description: Conventional assessment by physical therapists was followed by respiratory rehabilitation chest physiotherapy.Chest physical therapy for respiratory rehabilitation includes postural drainage, cough technique, forced expiratory technique, positive expiratory pressure, high-frequency chest wall compression, chest tapping, vibration, active breathing cycle technique, etc. All chest physiotherapy was performed by 1 therapist.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: chest physiotherapy
Description: Conventional assessment by physical therapists was followed by respiratory rehabilitation chest physiotherapy.Chest physical therapy for respiratory rehabilitation includes postural drainage, cough technique, forced expiratory technique, positive expiratory pressure, high-frequency chest wall compression, chest tapping, vibration, active breathing cycle technique, etc. All chest physiotherapy was performed by 1 therapist.
Study: NCT06641102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Guided Program (Tier 1)
Description: The study intervention is a smartphone application.~Tier 1: self-guided program, includes videos, guided meditations, and worksheets that are delivered to users in 10 different topical modules. Two modules are delivered per week, with email reminders. It will emphasize that PRT is a practice that requires users to come back to the material regularly to help retrain the brain often (just like how you need to practice and complete exercises between PT sessions).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coach Assisted Program (Tier 3)
Description: The study intervention is a smartphone application.~Tier 3: one-on-one coaching program that sets users up with trained PRT coaches who will walk them through the program individually. Users will meet with the assigned coaches once per week for an hour-long Zoom-hosted session that covers the same information as Tier 1, however in a completely personal and individualized way, focusing on the content that is most relevant for the user/patient at the time of the session. Tier 3 users will also receive materials from their coaches (e.g. videos, meditations, etc.) to support their own practice between session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: SOC is defined as a comprehensive clinical care plan, including a consultation with physiatrist and prescribed interventions, which will capture a comparison representative of all potential interventions that are recommended for an individual.
Study: NCT06561243

Intervention type: DRUG
Intervention: BTK inhibitor (Ibrutinib or Acalabrutinib)
Description: Adult patients with a chronic B-cell malignancy included in this study will be separate into 2 groups according to the BTK inhibitor (ibrutinib and acalabrutinib)

Intervention type: DRUG
Intervention: BTK inhibitor (Ibrutinib or Acalabrutinib)
Description: Adult patients with a chronic B-cell malignancy included in this study will be separate into 2 groups according to the BTK inhibitor (ibrutinib and acalabrutinib)
Study: NCT05849246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed
Description: Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous.~Other Name: Tusamitamab ravtansine. Other Name: Tyvyt®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sintilimab+Carboplatin or Cisplatin+Pemetrexed
Description: Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tusamitamab ravtansine+Sintilimab
Description: Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous.~Other Name: Tusamitamab ravtansine. Other Name: Tyvyt®
Study: NCT06564922

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counselling
Description: Counselling was given for treatment group.
Study: NCT06639672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy+PD-1 inhibitor+8Gy x 3f
Description: Radiotherapy: 8Gy x 3f, once every other day; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy+PD-1 inhibitor+16Gy x 1f
Description: Radiotherapy: 16Gy x 1f; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy+PD-1 inhibitor+2.67Gy x 15f
Description: Radiotherapy: 2.67Gy x 15f; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy+PD-1 inhibitor+0.5Gy x 12-18f
Description: Radiotherapy: 0.5Gy x 12-18f; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
Study: NCT06642272

Intervention type: DRUG
Group type: OTHER
Intervention: Empagliflozin 10 MG
Description: Once daily

Intervention type: DRUG
Group type: OTHER
Intervention: Dapagliflozin 10 MG
Description: Once daily
Study: NCT06642220

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Y-90 Selective Internal Radiation Therapy (SIRT)
Description: Y-90 radioembolization will be performed using glass spheres to treat non-metastatic RCC within the kidney.
Study: NCT06640166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: encorafenib + cetuximab + FOLFIRI
Description: encorafenib plus cetuximab beyond progression in combination with irinotecan-based doublet chemoterapy (FOLFIRI) as follows:~* encorafenib 300 mg (75 mgx4 hard capsules) orally once daily;~* cetuximab 500 mg/sqm iv every 14 days;~* FOLFIRI iv every 14 days (Irinotecan 180 mg/sqm, Folinic Acid 400 mg/sqm, 5Fluorouracil 400 mg/sqm iv bolus and 2400 mg/sqm iv continuous infusion over 46-48 hours).
Study: NCT06641219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: One single intravenous injection of [177Lu]Lu-BQ7876
Description: One single intravenous injection of 600-800 MBq \[177Lu\]Lu-BQ7876 in prostate cancer patients.
Study: NCT06638541

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prostate radical radiotherapy
Description: Radiation: De-escalated radiotherapy to be delivered on the Elekta Unity MR-linac
Study: NCT05792787

Intervention type: DIAGNOSTIC_TEST
Intervention: Echo-color-doppler
Description: To perform the initial screening patients will undergo panoramic radiography and clinical examination followed by periapical radiographs of the teeth suspected of AP using the long cone paralleling technique with a film holder. The following parameters will be recorded:~1. The number of decayed, missing and filled teeth (DMFT index)~2. The number of teeth with AP~3. Periapical Index Score All individuals will undergo a cardiovascular examination in the Unit of Vascular Surgery, University of Siena (Siena, Italy). The cardiovascular assessment included physical examination, blood pressure measurement, past medical history and echo-color-doppler for the assessment of carotid intima-media thickness (cIMT), presence of abdominal aortic aneurysm and presence of peripheral pulses.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echo-color-doppler
Description: To perform the initial screening patients will undergo panoramic radiography and clinical examination followed by periapical radiographs of the teeth suspected of AP using the long cone paralleling technique with a film holder. The following parameters will be recorded:~1. The number of decayed, missing and filled teeth (DMFT index)~2. The number of teeth with AP~3. Periapical Index Score All individuals will undergo a cardiovascular examination in the Unit of Vascular Surgery, University of Siena (Siena, Italy). The cardiovascular assessment included physical examination, blood pressure measurement, past medical history and echo-color-doppler for the assessment of carotid intima-media thickness (cIMT), presence of abdominal aortic aneurysm and presence of peripheral pulses.
Study: NCT06638541

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Prostate radical radiotherapy
Description: Radiation: De-escalated radiotherapy to be delivered on the Elekta Unity MR-linac
Study: NCT06641700

Intervention type: DIAGNOSTIC_TEST
Intervention: diagnosed with gastric cancer
Description: Pathological biopsy confirmed the diagnosis of gastric cancer.
Study: NCT06458998

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Navigation
Description: Clinical Resource Hub (CRH) providers include a small group of nurses, advance practice providers, and physicians who work to improve care across a range of measures using virtual PN. CRH providers will 1) use existing dashboards to identify at-risk Veterans, 2) conduct Veteran outreach (two calls, one letter) to provide education, problem solve, and offer screening, 3) order and schedule HCC or CRC screening tests, and 4) provide reminders and follow up on results.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Implementation Facilitation
Description: Facilitators will provide 20 hours of virtual facilitation to site teams, through 1-hour meetings every other week and ad hoc meetings, over 12 months. They will guide site teams through a seven-step playbook called Getting To Implementation (GTI), which uses a series of tools to select context-specific strategies.
Study: NCT04869384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminders and feedback to improve adherence
Description: Subjects will receive reminders and feedback to improve their adherence.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No reminders and feedback to improve adherence
Description: Subjects will not receive reminders and feedback to improve their adherence.
Study: NCT06161181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Decision Support System
Description: TREAT (TREatment Adherence SupporT) is a web-based DSS that comprises four sections:~i) Metastatic Breast Cancer: contains information about MBC and its physical and psychological consequences;~ii) Adherence to Cancer Therapies: contains information about adherence in the cancer population;~iii) Promoting Adherence: contains information about resources, barriers, and available interventions used to foster adherence;~iv) My Adherence Diary.